Wegovy HD 7.2mg Approved: The Strongest Semaglutide Dose Yet

The FDA just approved Wegovy HD — semaglutide at 7.2mg, the highest dose ever — with 20.7% average weight loss in clinical trials. Here's the full breakdown.

What Makes Wegovy HD Different

Wegovy HD is semaglutide at three times the current standard Wegovy dose (7.2mg vs 2.4mg). It represents the most potent single-agent GLP-1 medication ever approved by the FDA, closing the gap with dual-agonist medications like tirzepatide.

The approval came through the Competitive New Product Voucher (CNPV) pilot program — a fast-track pathway for drugs addressing national health priorities. The entire review process took just 54 days from filing, a dramatic acceleration compared to the standard 10-month timeline.

STEP UP Trial: The Numbers

The STEP UP phase 3 trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Here's how the results compare to other approved GLP-1 doses:

Medication	Dose	Mean Weight Loss	≥20% Achievement
Wegovy HD	7.2mg weekly	20.7%	~50%
Wegovy (standard)	2.4mg weekly	~15%	~32%
Oral Wegovy	25mg daily	16.6%	~34%
Zepbound (tirzepatide)	15mg weekly	20.9%	~57%

At 20.7%, Wegovy HD brings semaglutide efficacy into tirzepatide territory for the first time — with one in three participants losing 25% or more of their body weight.

Safety Profile at Higher Doses

The side effect profile is consistent with lower semaglutide doses, with gastrointestinal effects (nausea, diarrhea, vomiting) remaining the most commonly reported. One new finding at this dose level:

• Altered skin sensation — sensitivity, pain, or burning reported more frequently than at lower doses
• The FDA is conducting further investigation into this specific reaction
• Symptoms generally resolve on their own or with dose reduction

What This Means for Compounded Semaglutide

Wegovy HD arrives during a pivotal moment for the compounded GLP-1 market. The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List on April 30, 2026, with public comments due by June 29.

More FDA-approved dose options could accelerate the regulatory argument against compounding — if patients can access effective doses through approved channels, the "clinical need" justification for compounding weakens further.

However, the price gap remains the central issue. Compounded semaglutide runs $130-$300/month through most telehealth providers, while brand-name pricing (even with the oral Wegovy at $149) still represents a premium for many patients.

Current Provider Pricing

Availability Timeline

Novo Nordisk expects to launch Wegovy HD in a single-dose pen format starting mid-2026. This adds to the growing semaglutide product line:

• Wegovy 2.4mg injection — available since 2021
• Oral Wegovy 25mg tablet — launched January 2026 ($149/month)
• Wegovy HD 7.2mg injection — approved May 2026, expected mid-2026 launch

The Bottom Line

Wegovy HD at 7.2mg delivers the most weight loss ever recorded for a semaglutide product — 20.7% average, with one in three patients exceeding 25%. This brings single-agonist semaglutide into the same efficacy range as dual-agonist tirzepatide. For patients who've plateaued on standard doses, it represents a meaningful step up. Current compounded and brand-name options remain available while Wegovy HD ramps up production.